JP5691053B2 - 化粧用組成物における新規な天然物質の使用 - Google Patents
化粧用組成物における新規な天然物質の使用 Download PDFInfo
- Publication number
- JP5691053B2 JP5691053B2 JP2010525388A JP2010525388A JP5691053B2 JP 5691053 B2 JP5691053 B2 JP 5691053B2 JP 2010525388 A JP2010525388 A JP 2010525388A JP 2010525388 A JP2010525388 A JP 2010525388A JP 5691053 B2 JP5691053 B2 JP 5691053B2
- Authority
- JP
- Japan
- Prior art keywords
- mannoprotein
- cosmetic
- composition
- hair
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 101
- 239000002537 cosmetic Substances 0.000 title claims description 68
- 239000005445 natural material Substances 0.000 title description 4
- 102100024023 Histone PARylation factor 1 Human genes 0.000 claims description 96
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 claims description 86
- 239000000463 material Substances 0.000 claims description 12
- 108010005335 mannoproteins Proteins 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 241000235649 Kluyveromyces Species 0.000 claims description 3
- 108010064983 Ovomucin Proteins 0.000 claims description 3
- 241000006364 Torula Species 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 1
- 230000007071 enzymatic hydrolysis Effects 0.000 claims 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 51
- 238000011282 treatment Methods 0.000 description 48
- 210000004209 hair Anatomy 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 40
- 238000000034 method Methods 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 24
- 102000008186 Collagen Human genes 0.000 description 22
- 108010035532 Collagen Proteins 0.000 description 22
- 229920001436 collagen Polymers 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 18
- 239000000654 additive Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 12
- 210000002374 sebum Anatomy 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 11
- 229920002674 hyaluronan Polymers 0.000 description 11
- 229960003160 hyaluronic acid Drugs 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 208000001840 Dandruff Diseases 0.000 description 10
- 102000016942 Elastin Human genes 0.000 description 10
- 108010014258 Elastin Proteins 0.000 description 10
- 229920002549 elastin Polymers 0.000 description 10
- 230000003020 moisturizing effect Effects 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- 206010039792 Seborrhoea Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 230000003712 anti-aging effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000008742 seborrheic dermatitis Diseases 0.000 description 8
- 201000004384 Alopecia Diseases 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000003662 hair growth rate Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 235000014101 wine Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- -1 cerides Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000003752 improving hair Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FRGAIZLZPOROJH-BKIJVIAGSA-N [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]propoxy]oxan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO[C@H]1O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1O FRGAIZLZPOROJH-BKIJVIAGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 208000024349 endocrine alopecia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000010909 process residue Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Cosmetics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明の主題は、化粧用組成物及び皮膚用組成物における新規な天然物質の使用である。
マンノプロテインは、特に酵母の細胞壁に見いだされるタンパク質に結合したマンナンであり、そこでは構造機能および/または抗原機能を有する。
マンノプロテインの保湿特性、アンチ-エイジング特性、引き締め特性
材料と方法
(i)マンノプロテイン
ヨーロッパ特許EP 1 094117号に記載されている方法に従って得られるマンノプロテインを水溶液にし、0.04mg/ml、0.08mg/ml、0.016mg/ml、0.032mg/mlいずれかの濃度で試験する。
試験は、96ウエルのマイクロプレートのウエル内のKSFM培地(無血清)に植えた正常なヒト表皮ケラチノサイトNHEKで実施する。さまざまな濃度のマンノプロテインの存在下で脂質の合成とヒアルロン酸の合成を評価する。条件ごとに3つの培養ウエルを用意する。
陰性対照は培地だけで構成する。
正常なヒト真皮線維芽細胞(NHDF)と老化した正常なヒト真皮線維芽細胞(AgNHDF)を、96ウエルのマイクロプレートのウエル内のKSFM培地+10%FCSに播く。試験は、KSFM培地+1%FCSの中で実施する。2つの培地には、2 mMのL-グルタミンと、50 UI/mlのペニシリンと、50 μg/mlのストレプトマイシンも補足する。FCS(ウシ胎仔血清)と、L-グルタミンと、ペニシリンと、ストレプトマイシンは、インヴィトロジェン社から取得した。培養を37℃、5%CO2で実施する。正常な線維芽細胞は、8継代目のプールF2からの線維芽細胞であり、老化した線維芽細胞は、18継代目のプールF2からの線維芽細胞である。
陰性対照は培地だけで構成する。
老化した正常なヒト表皮線維芽細胞(AgNHDF)で試験を実施する。
ダンネット多重比較検定を利用し、分散分析(ANOVA)によってグループ間の比較を行なう。
i)表皮に対する保湿効果の評価
マンノプロテイン溶液の存在下では、ケラチノサイトによる脂質とヒアルロン酸の合成が陰性対照と比べて活性化される。
マンノプロテイン溶液の存在下では、(陰性対照と比べて)細胞増殖の活性化と、細胞外マトリックスの主要構成成分の合成の増加が観察される。
特に、コラーゲンの合成に関して以下の表1に示した結果が得られる。
マンノプロテイン溶液の存在下では、陰性対照と比べ、コラーゲンの発現レベルの増加が観察されるとともに、コラーゲンの成熟が、マトリックスの周辺へのコラーゲンの堆積によって明らかになる。真皮等価物の密度が増大する(直径と細胞数の比が陰性対照よりも小さい)ことで、コラーゲン格子がよりよく収縮する。さらに、線維芽細胞によるエラスチンの合成が陰性対照と比べて活性化される。これらの現象はすべて、マンノプロテインが真皮の生体力学的品質を(特に弾性と圧縮性に関して)改善することを示している。
抗脂漏特性と抗座瘡特性
材料と方法
マンノプロテイン溶液を、皮膚または頭皮に過剰脂漏症がある対象のそれぞれ皮膚または頭皮に適用する。
マンノプロテイン溶液により、分泌される皮脂の量を減らすことができる。
毛管現象への応用
材料と方法
(i)マンノプロテイン
ヨーロッパ特許EP 1 094117号に記載されている方法に従って得られるマンノプロテインを水溶液にする。
フケに悩まされている対象の頭皮にマンノプロテイン溶液を適用する。マンノプロテイン溶液で処置した後、パッチを処置した領域だけに取り付けて頭皮からのフケを回収する。
毛髪の成長速度を以下のようにして評価する:処置前に対象の毛髪の束を根元から2〜3 cmにわたって着色する;次にマンノプロテイン溶液を頭皮に適用する;毛の根元と着色開始点の距離を測定する。
毛髪の表面で反射される光の量と強度を測定することによって毛髪の光沢を調べる。そうするため、毛髪の交差偏光写真と非偏光写真を撮影する。次にその2枚の写真をグレー・スケールに変換し、2枚の写真の間で光を差し引くことによって毛髪の光沢を得る。
触ったときの毛髪の柔らかさを評価する資格のある3人の審査員による感覚的分析によって毛髪の柔らかさを評価する。
干渉顕微鏡を用いて毛髪の表面の形状を測定することによって毛髪の再構成を評価する。
開いた鱗、
鱗の長さ、
表面の形状、すなわち粗さ。
マンノプロテイン溶液を毛管現象に応用することにより、抗フケ効果を得るとともに毛髪の成長を増大させることができる。
手触り添加剤と乳化賦形剤の機能
材料と方法
(i)マンノプロテイン
ヨーロッパ特許EP 1 094117号に記載されている方法に従って得られるマンノプロテインを水溶液にする。
マンノプロテインの手触り特性と膜形成特性をさまざまな方法で評価する。その方法とは、レーザー光散乱の測定による粒子サイズの分析、レオロジー研究(降伏値、粘性率、日焼けd(DMAとも呼ばれる))、さまざまな温度と期間での安定性試験(導電率、粒度分布、粘性率、色、フレグランス)、皮膚への広がりである。
アニオン系:セラリューションH、
非イオン系:テゴ・ケア450、
非イオン系をベースとしていてTiO2を含む日焼け止めローション
ゲル。
ポリマー性テクスチャライザ(texturizer)が化粧用組成物で広く用いられている。これらのテクスチャライザは、クリーム、ゲル、ローションといったタイプの組成物を製造するためのカギとなる製品である。テクスチャライザは、多彩な化学的添加剤の存在下でその特性を保持せねばならない。
Claims (5)
- 手触り(texturizing)物質として真菌の細胞壁から酵素的加水分解により抽出したマンノプロテイン、およびもう1つの手触り(texturizing)物質としてキサンタンガムを含む皮膚化粧用組成物であって、マンノプロテインのキサンタンガムに対する重量比が1:5〜1:3であり、該組成物がポリフェノールおよびオボムチンを含まない、組成物。
- マンノプロテインのキサンタンガムに対する重量比が1:4である、請求項1に記載の組成物。
- 前記マンノプロテインが、サッカロミセス(Saccharomyces)、クルイベロマイセス(Kluyveromyces)、トルラ(Torula)またはカンジダ(Candida)に由来することを特徴とする、請求項1又は2に記載の組成物。
- 前記マンノプロテインが、サッカロミセス・セレビジエ(Saccharomyces cerevisiae)に由来する、請求項3に記載の組成物。
- 0.01%〜20%のマンノプロテインを含む、請求項1〜4のいずれか1項に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706701 | 2007-09-25 | ||
| FR0706701A FR2921260B1 (fr) | 2007-09-25 | 2007-09-25 | Utilisation d'un nouvel agent naturel dans des compositions cosmetiques |
| PCT/FR2008/001319 WO2009074735A2 (fr) | 2007-09-25 | 2008-09-23 | Utilisation d'un nouvel agent naturel dans des compositions cosmetiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540421A JP2010540421A (ja) | 2010-12-24 |
| JP5691053B2 true JP5691053B2 (ja) | 2015-04-01 |
Family
ID=39537487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525388A Active JP5691053B2 (ja) | 2007-09-25 | 2008-09-23 | 化粧用組成物における新規な天然物質の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9636290B2 (ja) |
| EP (2) | EP2567688B1 (ja) |
| JP (1) | JP5691053B2 (ja) |
| KR (1) | KR101603051B1 (ja) |
| CN (1) | CN101815500B (ja) |
| AU (1) | AU2008334527B2 (ja) |
| BR (1) | BRPI0816012A2 (ja) |
| CA (1) | CA2700424C (ja) |
| DK (2) | DK2567688T3 (ja) |
| ES (2) | ES2549534T3 (ja) |
| FR (1) | FR2921260B1 (ja) |
| HR (2) | HRP20161625T1 (ja) |
| HU (2) | HUE025403T2 (ja) |
| LT (1) | LT2203153T (ja) |
| MX (1) | MX2010003258A (ja) |
| PL (2) | PL2567688T3 (ja) |
| RU (1) | RU2491051C2 (ja) |
| SI (2) | SI2203153T1 (ja) |
| WO (1) | WO2009074735A2 (ja) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10241158B2 (en) | 2015-02-04 | 2019-03-26 | Lockheed Martin Corporation | Apparatus and method for estimating absolute axes' orientations for a magnetic detection system |
| US9557391B2 (en) | 2015-01-23 | 2017-01-31 | Lockheed Martin Corporation | Apparatus and method for high sensitivity magnetometry measurement and signal processing in a magnetic detection system |
| US9638821B2 (en) | 2014-03-20 | 2017-05-02 | Lockheed Martin Corporation | Mapping and monitoring of hydraulic fractures using vector magnetometers |
| US9823313B2 (en) | 2016-01-21 | 2017-11-21 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensor with circuitry on diamond |
| US9910104B2 (en) | 2015-01-23 | 2018-03-06 | Lockheed Martin Corporation | DNV magnetic field detector |
| US9551763B1 (en) | 2016-01-21 | 2017-01-24 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensor with common RF and magnetic fields generator |
| US9541610B2 (en) | 2015-02-04 | 2017-01-10 | Lockheed Martin Corporation | Apparatus and method for recovery of three dimensional magnetic field from a magnetic detection system |
| US9817081B2 (en) | 2016-01-21 | 2017-11-14 | Lockheed Martin Corporation | Magnetometer with light pipe |
| US9614589B1 (en) | 2015-12-01 | 2017-04-04 | Lockheed Martin Corporation | Communication via a magnio |
| US10338162B2 (en) | 2016-01-21 | 2019-07-02 | Lockheed Martin Corporation | AC vector magnetic anomaly detection with diamond nitrogen vacancies |
| US9590601B2 (en) | 2014-04-07 | 2017-03-07 | Lockheed Martin Corporation | Energy efficient controlled magnetic field generator circuit |
| US9910105B2 (en) | 2014-03-20 | 2018-03-06 | Lockheed Martin Corporation | DNV magnetic field detector |
| US10520558B2 (en) | 2016-01-21 | 2019-12-31 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensor with nitrogen-vacancy center diamond located between dual RF sources |
| US10168393B2 (en) | 2014-09-25 | 2019-01-01 | Lockheed Martin Corporation | Micro-vacancy center device |
| US9853837B2 (en) | 2014-04-07 | 2017-12-26 | Lockheed Martin Corporation | High bit-rate magnetic communication |
| US10120039B2 (en) | 2015-11-20 | 2018-11-06 | Lockheed Martin Corporation | Apparatus and method for closed loop processing for a magnetic detection system |
| CA2975103A1 (en) | 2015-01-28 | 2016-08-04 | Stephen M. SEKELSKY | In-situ power charging |
| WO2016190909A2 (en) | 2015-01-28 | 2016-12-01 | Lockheed Martin Corporation | Magnetic navigation methods and systems utilizing power grid and communication network |
| EP3371614A1 (en) | 2015-11-04 | 2018-09-12 | Lockheed Martin Corporation | Magnetic band-pass filter |
| WO2017087014A1 (en) | 2015-11-20 | 2017-05-26 | Lockheed Martin Corporation | Apparatus and method for hypersensitivity detection of magnetic field |
| WO2017123261A1 (en) | 2016-01-12 | 2017-07-20 | Lockheed Martin Corporation | Defect detector for conductive materials |
| WO2017127090A1 (en) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Higher magnetic sensitivity through fluorescence manipulation by phonon spectrum control |
| GB2562958A (en) | 2016-01-21 | 2018-11-28 | Lockheed Corp | Magnetometer with a light emitting diode |
| WO2017127098A1 (en) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensed ferro-fluid hydrophone |
| US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
| CA3018866C (en) | 2016-03-31 | 2024-03-26 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| US10330744B2 (en) | 2017-03-24 | 2019-06-25 | Lockheed Martin Corporation | Magnetometer with a waveguide |
| US10527746B2 (en) | 2016-05-31 | 2020-01-07 | Lockheed Martin Corporation | Array of UAVS with magnetometers |
| US10677953B2 (en) | 2016-05-31 | 2020-06-09 | Lockheed Martin Corporation | Magneto-optical detecting apparatus and methods |
| US10408890B2 (en) | 2017-03-24 | 2019-09-10 | Lockheed Martin Corporation | Pulsed RF methods for optimization of CW measurements |
| US10345396B2 (en) | 2016-05-31 | 2019-07-09 | Lockheed Martin Corporation | Selected volume continuous illumination magnetometer |
| US20170343621A1 (en) | 2016-05-31 | 2017-11-30 | Lockheed Martin Corporation | Magneto-optical defect center magnetometer |
| US10371765B2 (en) | 2016-07-11 | 2019-08-06 | Lockheed Martin Corporation | Geolocation of magnetic sources using vector magnetometer sensors |
| US10359479B2 (en) | 2017-02-20 | 2019-07-23 | Lockheed Martin Corporation | Efficient thermal drift compensation in DNV vector magnetometry |
| US10281550B2 (en) | 2016-11-14 | 2019-05-07 | Lockheed Martin Corporation | Spin relaxometry based molecular sequencing |
| US10338163B2 (en) | 2016-07-11 | 2019-07-02 | Lockheed Martin Corporation | Multi-frequency excitation schemes for high sensitivity magnetometry measurement with drift error compensation |
| US10228429B2 (en) | 2017-03-24 | 2019-03-12 | Lockheed Martin Corporation | Apparatus and method for resonance magneto-optical defect center material pulsed mode referencing |
| US10274550B2 (en) | 2017-03-24 | 2019-04-30 | Lockheed Martin Corporation | High speed sequential cancellation for pulsed mode |
| US10345395B2 (en) | 2016-12-12 | 2019-07-09 | Lockheed Martin Corporation | Vector magnetometry localization of subsurface liquids |
| US10145910B2 (en) | 2017-03-24 | 2018-12-04 | Lockheed Martin Corporation | Photodetector circuit saturation mitigation for magneto-optical high intensity pulses |
| US10317279B2 (en) | 2016-05-31 | 2019-06-11 | Lockheed Martin Corporation | Optical filtration system for diamond material with nitrogen vacancy centers |
| US10571530B2 (en) | 2016-05-31 | 2020-02-25 | Lockheed Martin Corporation | Buoy array of magnetometers |
| EP3544575A1 (en) | 2016-11-23 | 2019-10-02 | GOJO Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| US10459041B2 (en) | 2017-03-24 | 2019-10-29 | Lockheed Martin Corporation | Magnetic detection system with highly integrated diamond nitrogen vacancy sensor |
| US10371760B2 (en) | 2017-03-24 | 2019-08-06 | Lockheed Martin Corporation | Standing-wave radio frequency exciter |
| US10338164B2 (en) | 2017-03-24 | 2019-07-02 | Lockheed Martin Corporation | Vacancy center material with highly efficient RF excitation |
| US10379174B2 (en) | 2017-03-24 | 2019-08-13 | Lockheed Martin Corporation | Bias magnet array for magnetometer |
| WO2019158637A1 (en) * | 2018-02-14 | 2019-08-22 | Danstar Ferment Ag | Yeast extract compositions for treating keratin materials |
| WO2020004568A1 (ja) * | 2018-06-28 | 2020-01-02 | アサヒグループホールディングス株式会社 | エクオール産生促進剤およびそれを含むエクオール産生促進用食品または飲料組成物 |
| CN111297725A (zh) * | 2018-12-11 | 2020-06-19 | 安琪酵母股份有限公司 | 恢复皮肤屏障功能的护肤组合物及其制备方法和应用 |
| FR3125718B1 (fr) | 2021-08-02 | 2025-04-04 | Soc Ind Limousine Dapplication Biologique | Principe actif comprenant des oligo-glucanes issus de la fraction cytosolique de Saccharomyces cerevisiae et ses utilisations cosmétiques |
| KR20250167574A (ko) * | 2023-04-14 | 2025-12-01 | 미츠비시 쇼지 라이프사이언스 가부시키가이샤 | 효모 추출물을 포함하는 외용 조성물 |
| CN121079072A (zh) * | 2023-05-09 | 2025-12-05 | 三菱商事生命科学株式会社 | 酵母细胞壁的化妆用组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2726284B1 (fr) | 1994-10-31 | 1996-12-27 | Inst Oenologie | Produit biologique pour la stabilisation physico-chimique d'un vin |
| EP0790316A3 (en) * | 1996-02-16 | 1999-02-10 | Quest International B.V. | Emulsifier from yeast |
| GB9608145D0 (en) * | 1996-04-19 | 1996-06-26 | British Tech Group | Wound healing |
| FR2750434B1 (fr) | 1996-06-26 | 1998-08-21 | Applic De Rech Et De Conseils | Produit de stabilisation proteique des vins |
| US6358516B1 (en) * | 1998-08-21 | 2002-03-19 | Norris R. Harod | One-step system for cleansing, conditioning, and treating the skin |
| WO2000044367A2 (en) * | 1999-02-01 | 2000-08-03 | Dermal Research Laboratories, Inc. | A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| DE19911056B9 (de) * | 1999-03-12 | 2005-09-08 | Biotec Asa | Kosmetische Zubereitungen und deren Verwendung |
| FR2800076B1 (fr) | 1999-10-22 | 2003-11-14 | Lesaffre & Cie | Mannoproteines solubles |
| AR027016A1 (es) | 1999-12-21 | 2003-03-12 | Dsm Nv | Proceso para la estabilizacion de vino |
| FR2802812B1 (fr) * | 1999-12-22 | 2002-08-23 | Serobiologiques Lab Sa | Utilisation de residus issus de la fabrication du vin pour la fabrication de preparations cosmetiques et/ou pharmaceutiques. |
| FR2804864B1 (fr) | 2000-02-11 | 2003-04-04 | Serobiologiques Lab Sa | Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie |
| EP1132399A1 (en) | 2000-03-08 | 2001-09-12 | Universitair Medisch Centrum Utrecht | Mannoproteins or equivalents thereof for use in modulating neutrophil migration |
| EP1414865B1 (en) * | 2000-08-03 | 2014-04-09 | Abac R & D Ag | Isolation of glucan particles and uses thereof |
| AUPS052802A0 (en) * | 2002-02-15 | 2002-03-07 | Praxis Pharmaceuticals International Pty Ltd | Carbohydrate-based anti-wrinkle and tissue remodelling compounds |
| US20050226822A1 (en) * | 2002-04-25 | 2005-10-13 | Gaba International Ag | Oral care products containing ovomucin |
| WO2004003160A2 (en) * | 2002-06-27 | 2004-01-08 | University Of Washington | Use of adhesion molecules as bond stress-enhanced nanoscale binding switches |
| US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
| WO2006036817A2 (en) | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Fungal variants and uses thereof |
| AU2005318196B2 (en) | 2004-12-23 | 2010-08-19 | Dsm Ip Assets B.V. | Process to improve activity of mannoprotein as wine stabiliser |
| AU2006292992B2 (en) | 2005-09-22 | 2012-03-08 | Suntory Holdings Limited | Gene encoding cell wall mannoprotein and use thereof |
| GB0609901D0 (en) * | 2006-05-18 | 2006-06-28 | Sinclair Pharmaceuticals Ltd | Method |
| JP2008222655A (ja) | 2007-03-14 | 2008-09-25 | Asahi Breweries Ltd | 皮膚外用剤 |
-
2007
- 2007-09-25 FR FR0706701A patent/FR2921260B1/fr active Active
-
2008
- 2008-09-23 WO PCT/FR2008/001319 patent/WO2009074735A2/fr not_active Ceased
- 2008-09-23 SI SI200831725A patent/SI2203153T1/sl unknown
- 2008-09-23 KR KR1020107006905A patent/KR101603051B1/ko active Active
- 2008-09-23 ES ES12190685.3T patent/ES2549534T3/es active Active
- 2008-09-23 HR HRP20161625TT patent/HRP20161625T1/hr unknown
- 2008-09-23 SI SI200831505T patent/SI2567688T1/sl unknown
- 2008-09-23 BR BRPI0816012A patent/BRPI0816012A2/pt not_active Application Discontinuation
- 2008-09-23 RU RU2010116160/15A patent/RU2491051C2/ru active
- 2008-09-23 EP EP12190685.3A patent/EP2567688B1/fr active Active
- 2008-09-23 LT LTEP08860035.8T patent/LT2203153T/lt unknown
- 2008-09-23 CA CA2700424A patent/CA2700424C/fr active Active
- 2008-09-23 AU AU2008334527A patent/AU2008334527B2/en active Active
- 2008-09-23 HU HUE12190685A patent/HUE025403T2/en unknown
- 2008-09-23 EP EP08860035.8A patent/EP2203153B1/fr active Active
- 2008-09-23 US US12/679,777 patent/US9636290B2/en active Active
- 2008-09-23 HU HUE08860035A patent/HUE029832T2/en unknown
- 2008-09-23 PL PL12190685T patent/PL2567688T3/pl unknown
- 2008-09-23 DK DK12190685.3T patent/DK2567688T3/en active
- 2008-09-23 ES ES08860035.8T patent/ES2608492T3/es active Active
- 2008-09-23 CN CN2008801087344A patent/CN101815500B/zh active Active
- 2008-09-23 DK DK08860035.8T patent/DK2203153T3/en active
- 2008-09-23 PL PL08860035T patent/PL2203153T3/pl unknown
- 2008-09-23 MX MX2010003258A patent/MX2010003258A/es active IP Right Grant
- 2008-09-23 JP JP2010525388A patent/JP5691053B2/ja active Active
-
2015
- 2015-09-21 HR HRP20150996TT patent/HRP20150996T1/hr unknown
-
2016
- 2016-10-31 US US15/338,972 patent/US10292926B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5691053B2 (ja) | 化粧用組成物における新規な天然物質の使用 | |
| RU2491910C9 (ru) | Применение натуральных активных веществ в косметических или терапевтических композициях | |
| JP7094967B2 (ja) | 化粧品向けの使用のためのアニゴザントス・フラビダスの抽出物 | |
| JP2022511023A (ja) | シスツス・モンスペリエンシス(Cistus monspeliensis)の抽出物の新規な化粧品的及び皮膚科学的使用 | |
| JP2025502259A (ja) | 新規な使用 | |
| FR3004347A1 (fr) | Composition cosmetique comprenant une huile essentielle de sauge et son utilisation | |
| FR3008890B1 (fr) | Extrait de chene, composition comprenant ledit extrait et utilisations notamment cosmetiques | |
| JP2022543141A (ja) | ヤナギラン(Epilobium angustifolium)抽出物の新規な化粧用使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130611 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130910 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130918 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131211 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140916 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141209 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5691053 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |